% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • drrc1949 drrc1949 Sep 23, 2013 12:29 PM Flag

    Vascepa Reduces CVD Risk - New Study Reveals !!!!!

    An about to be published study in the Journal of Atherosclerosis and Thrombosis states incontravertibly that EPA administration, the primary ingredient in Vascepa, reduces the risk of CVD.

    From the Paper: "EPA metabolizes into bio-active PGI3 (prostaglandin-3), It is assumed that similar to PGI2, PGI3 inhibits platelet aggregation, vascular contraction, myocardial ischemic injury and arteriosclerosis and induces neoangiogenesis. Therefore, it is speculated that the CVD risk reduction induced by EPA is also associated with the effects of PGI3 in addition to the numerous effects of EPA itself (such as TG reduction, inflammation inhibition and improvements in plasma membrane fluidity). This hypothesis is confirmed by the following findings: an increased CVD risk was found to be associated with a reduction in the EPA/AA ratio, and the EPA/AA ratio was found to be positively correlated with the (PGI2 + PGI3)/TXA2 (thromboxane A2) ratio. It is important to increase the PGI/TXA ratio in order to reduce the incidence of cardiovascular events.".

    That is EXACTLY what VASCEPA DOES !!!! And proving that Vascepa causes a reduction in CVD events is what we're looking for from the REDUCE-IT Trial. The results from this study guarantee the results from REDUCE-IT.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.06+0.08(+4.04%)Oct 2 4:00 PMEDT